GDUFA III Talks Completed; Fees will Fund Inspection, Complex Generic Improvements

 
• By Derrick Gingery

Post-warning letter meetings for manufacturing issues and updates to the complex product meeting process are included in the user fee extension agreement.

Agreement reached
GDUFA III was the last of three FDA human drug and biologic user fee renewal agreements to be completed. • Source: Alamy

More from User Fees

More from Pathways & Standards